Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02756962 · ClinicalTrials.gov registry record · Phase 2

Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance

A Phase 2 study of Acute Myeloid Leukemia, sponsored by Washington University School of Medicine.

Active
Registry status
Phase 2
Development phase
107
Enrollment target
3
Study locations

NCT02756962 is a Phase 2 study of Acute Myeloid Leukemia that is active but no longer recruiting, run by Washington University School of Medicine. The registered enrollment target is 107 participants, roughly in line with the 115-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target. The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02756962, a Phase 2 study of Acute Myeloid Leukemia, is active but no longer recruiting, sponsored by Washington University School of Medicine.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
107 participants
Enrollment target
3
Study locations

Study Summary

The investigators will prospectively determine whether the relapse-free and overall survival in patients who have cleared their leukemia-associated mutations treated with standard consolidation chemotherapy is superior to what is expected based on historical controls. The investigators will also prospectively determine the relapse-free and overall survival of patients who have not cleared their mutations. Because the relapse rate of patients with persistent mutations is expected to be high, treatment with either standard of care consolidation therapy alone or alloSCT will be permitted, at the discretion of the treating physician.

Conditions Studied

Acute Myeloid Leukemia

Interventions

  • DRUG Cytarabine
  • PROCEDURE Bone marrow aspiration
  • PROCEDURE Allogeneic stem cell transplant
  • PROCEDURE Punch skin biopsy
  • DEVICE ClinSeq

Study Locations (3)

Florida

  • University of Florida - Gainesville

Missouri

  • Washington University School of Medicine - St Louis

New York

  • University of Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 107 participants
Start Date 2016-07-06
Est. Completion 2029-07-31
Phase Phase 2

Sponsor

Washington University School of Medicine

1,502 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02756962

The ClinicalTrials.gov registry entry for NCT02756962 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 107 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 115-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 5 interventions - of which Cytarabine is the first listed.

NCT02756962 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Florida, Missouri, New York.

Frequently Asked Questions

What is clinical trial NCT02756962 about?

NCT02756962 is a clinical study titled "Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance". The investigators will prospectively determine whether the relapse-free and overall survival in patients who have cleared their leukemia-associated mutations treated with standard consolidation chemotherapy is superior to what is expected based on historical controls. The investigators will also pro...

What is the current status of trial NCT02756962?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 107 participants. The study started on 2016-07-06. Estimated completion is 2029-07-31.

What conditions does trial NCT02756962 study?

This clinical trial studies the following conditions: Acute Myeloid Leukemia.

What interventions are being tested in trial NCT02756962?

The interventions under investigation include: Cytarabine (DRUG), Bone marrow aspiration (PROCEDURE), Allogeneic stem cell transplant (PROCEDURE), Punch skin biopsy (PROCEDURE), ClinSeq (DEVICE).

Who is sponsoring clinical trial NCT02756962?

This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02756962 being conducted?

This trial has 3 study locations across Florida, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Myeloid Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Acute Myeloid Leukemia

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.